Leonhart graduated from
Bemidji State University in 1978 with a bachelor's degree in
criminal justice, and began her career in law enforcement as a
patrol officer in the
Baltimore Police Department before entering the DEA in late 1980 as a
Special Agent. She became DEA's first female Special Agent in Charge in 1997. and submitted her nomination to the
United States Senate on October 3, 2003. The Senate confirmed her nomination on March 8, 2004. On April 15, 2008, the
White House announced that President Bush intended to nominate Leonhart to succeed Tandy as the next Administrator of DEA. Leonhart's nomination was received by the Senate the same day and referred to the
Senate Judiciary Committee. However, the committee did not hold any hearings on Leonhart's nomination, and on January 2, 2009, the nomination was returned to the President under the provisions of Senate Rule XXXI, paragraph 6 of the Standing Rules of the Senate pursuant to
sine die adjournment at the end of the
110th Congress. She is currently Chair of the D.A.R.E. Board of Directors.
DEA Administrator During Leonhart's testimony before the
Judiciary Committee, she was questioned by a member of the
Committee on Aging, Senator
Herb Kohl (D-WI), about her policy for nurses prescribing painkillers for patients in nursing homes. The problem of DEA interference during Leonhart's acting administratorship with the prescription of painkillers by nurses in nursing homes had come before the Committee on Aging. Unsatisfied with her responses to his questions, Senator Kohl threatened to put a hold on Leonhart's nomination that could have postponed the vote on her confirmation indefinitely. In correspondence between the Committee on Aging and the DEA, Senator Kohl received assurances that patients suffering intractable pain could receive painkillers prescribed by nurses. On December 22, 2010, the Senate confirmed Leonhart's nomination unanimously by voice vote. Administrator Leonhart faced a large increase in prescription drug overdoses due to the
opioid crisis. Regardless,
drug diversion enforcement actions against pharmaceutical companies declined sharply under her leadership, dropping from 131 in 2011 to 40 in 2014. ==Controversy==